Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MERIDIAN phase 2 pegcetacoplan trial in sporadic amyotrophic lateral sclerosis
jRCT2031230170Phase 2Active, not recruiting
- Sponsor
- Apellis Pharmaceuticals
- Start
- Aug 2021
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Pegcetacoplan with Placebo (2 arms). Primary endpoint: CAFS rank score at Week 52. Started Aug 2021; status: active, not recruiting.
02
Drugs
pegcetacoplan
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on jRCT2031230170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230170.